4 Tables and figures: Five yr OS was 49%, 15%, 11% and 0% for mENSAT stages III, IVa, IVb and IVc , respectively (p<0.0001). At multivariate analysis, mENS@T stage (HR:2.6, HR:3.8 or HR:4.9 for stage IVa, IVb, or IVc respectively, all p<0.0001) and 4 additional parameters were significantly associated to OS: age>50 years (HR:1.6, p<0.0001), presence of tumor or hormonal-related symptoms (HR:1.6, p=0.01 ;(HR:1.6, p=0.03) in model 1 but also R status (for R1/2/x HR:1.7, p=0.0006), grade (Weiss >6 and Ki67>20%, HR:1.3, p=0.06) in model 2.
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Introduction
Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated incidence of 0.7-2.0 cases per million habitant per year (1, 2) . ACC is considered one of the most aggressive solid tumor in oncology as testified by a 5-year survival below 15% for metastatic patients in four registries (3) (4) (5) (6) . Historically, ACC prognosis has been shown to be mainly driven by the presence of metastases and tumor resectability (7, 8) . More recently, the European Network for the Study of adrenal Tumors (ENS@T) classification of TNM stage and the resection status have refined prognostication (5, 6, 9, 10) .
Advanced ACC, defined as tumor stage III, in case of loco-regional spread, or stage IV, in case of distant metastases, represent 18-26% and 21-46% of ACC patients at diagnosis, respectively (3) (4) (5) (6) . Treatment options of these patients are limited (11) (12) (13) and no predictors of response is validated. The best way to stratify stage III and/or IV ACC patients prognosis is a matter of debate. Indeed, several studies have suggested that stage III patients with positive lymph nodes or vena cava invasion could have a similar prognosis than stage IV patients (9, 14, 15) . In stage IV ACC patients, the number of tumor affected organs has been reported to be of value in refining the prognosis of these patients as well (16) . In addition, several studies suggested that age, secretion of hormones, Weiss score and/or proliferative index and the resection (R) status may also affect the prognosis of these patients (10, (17) (18) (19) (20) . An improved prognostic stratification is therefore needed to better understand the heterogeneity of prognosis in advanced ACC as illustrated by the 2 to 190 months range overall survival reported in studies investigating treatment with mitotane (21) (22) (23) (24) (25) (26) .
The objective of this retrospective study was to refine the prognostic classification of advanced stage III and synchronous stage IV ACC patients. To achieve this goal, the ENS@T registry, encompassing a large number of ACC treated in expert centers from four European countries, was utilized. All parameters were captured based on per-investigator file and collected through a dedicated e-CRF.
Patients and Methods
Patients and data collection
Both registries had been approved by the local ethics committees of all partaking centers and all included patients had provided written informed consent. Based on previous reports that suggest a prognostic role for the Weiss score and or proliferative index in advanced ACC patients (18, 27) , we also first attempted to validate the best way to classify the pathological parameters as a Grading system for advanced stage III-IV ACC patients according to the median Weiss score and or Ki67 index based on the primary tumor analysis (Figure 2 ). Like for tumor burden, selection of parameters to express tumoral grade was performed graphically using Kaplan-Meier curves.
Evaluation of different stage III-IV definitions and tumoral grading systems
Statistical analysis
Descriptive analyses were performed using mean and standard-deviation for quantitative variables, and comparisons were performed using Student test (or non- The following variables were analysed for their potential prognostic value at univariate analysis: age (<50 or >50 years), gender, modality of diagnosis (tumor mass, incidental mass, hormonal hypersecretion), tumor size (0-50 mm, 50-100 mm, 100-200 mm and >200mm), best staging system as defined above, type of organ involved (lung, liver, bone, distant lymph nodes), R status and pathological grading as defined above.
Two multivariate analyses were performed: model 1 called "prior-surgery" analysed all prognostic parameters available at the time of ACC diagnosis. Model 2 called "post-surgery" analysed all prognostic parameters including the grading and R status. Statistical analysis was conducted using SAS software version 9.2.
Results
Population characteristics and follow-up data
The following exclusion criteria were applied to the 463 cases reviewed: age younger than 18 years old (15 patients), loss to follow-up (4 patients). Therefore, 444 patients constitute the studied population: 210 (47%) were classified ENS@T stage III and 234 (53%) were stage IV. The main clinical features are summarized in Table 2 . Briefly, the majority of patients were females (61%) with a median age of 51±14 years. Symptoms related to tumor mass were present in 163 (37%), hormonal hypersecretions were present in 144 (32%) patients including cortisol hypersecretion in 116 (80%) patients.
Based on TNM staging, 11 (2%) were staged as T1, 97 (22 %) as T2, 140 (32%) as Weiss score was captured in 327 cases (73%) and was found above 6 in 153 (47%) tumors. Ki67 index was captured in 226 patients (50%) and found above 20% in 123 (54%) of cases.
The median follow-up of patients was 55.2 months. Median overall survival was 24
months. The 1-, 2-and 5-yr survival rates were 71%, 50% and 27%, respectively. Three hundred and one patients (68%) died during the time of the study. Among the 143 patients still alive at the time of data freeze: 76 (53%) were alive with metastatic or recurrence disease and 63 (44%) without evidence of disease, status was unknown in 4 patients. Death was ACC-related in all cases except in six.
Evaluation of the best TNM and pathological classifications in advanced ACC patients
Both ENS@T and the mENS@T classification, as defined in Materials and Methods, were found more informative than UICC (Figure 1 ). Finally, because the first mENS@T classification was found to better stratify the prognosis of stage III-IV ACC patients we finally used the following mENS@T classification as defined by: stage III (T3-4N0M0) or, stage IVa, IVb, IVc according to the number of tumor organs involved including the primary tumor and lymph node status as "organ": 2, 3 or >3, respectively (Supplementary Figure 1 a-b , Table 1 ).
Regarding the grading, prognostic information but also the number of data available was taken into account. Both Ki67 and the Weiss score significantly discriminate OS outcome at univariate analysis. However, Ki67 capture was lacking in a significant number of patients.
Weiss score and/or Ki67 were available in 350 patients and the combination of the two pathological parameters (Weiss ≤ 6 and Ki67<20 vs Weiss >6 or Ki67≥20) allowed to significantly separate two subgroups of patients, in terms of OS (Figure 2a-c) . We finally classified the grading of advanced ACC patients according to the following classification as defined by: Weiss score > 6 or Ki67 ≥ 20% against Weiss score and Ki67 below these thresholds.
Prognostic factors for overall survival
Univariate analysis (Table 3) At univariate analysis, the following parameters were found to be significantly inversely associated with overall survival ( At multivariate analysis within model 1, the following parameters were found significantly and independently associated with an increased risk of death: age > 50 years (p<0.0001), the presence of symptoms related to tumor mass (p=0.01) or hormonal hypersecretion at diagnosis (p=0.03), the mENS@T stage (all p<0.0001).
Within In the following section the acronym GRAF for Grading, Resection status, Age, Functional symptoms is grouped together to refer to these four parameters.
Combination of prognostic parameters
We then attempted to refine the prognostic classification of ACC, combining mENS@T stage with the GRAF parameters Presence of age >50 yrs and/or functional symptoms was first combined with mENS@T stages within model 1 ( Figure 3 ). Presence of unfavourable Grading or R status was subsequently combined with mENS@T stages within model 2 ( Figure 4) . when tumoral grading and R status were unfavourable within model 2 ( Figure 4A ).
Five-years-OS of mENS@T stage IVa was 15% but ranged from 0 to 55% when age and functional symptoms were unfavourable or favourable within model 1 ( Figure 3B) respectively, and ranged from 16 to 46% when tumoral grading and R status were unfavourable or favourable within model 2 ( Figure 4B ).
Discussion
Based on the largest cohort of patients with advanced ACC investigated so far, this collaborative study of the ENS@T network allows to refine the prognostic classification of advanced ACC patients as defined by stage III or synchronous stage IV. A new mENS@T TNM classification for advanced ACC patients is proposed as well as four additional prognostic parameters named "GRAF parameters" confirmed as critical: Grading (G), R status (R), age (A) and presence of functioning symptoms, as defined as tumor-or hormone-related symptoms at diagnosis (F). Of note, the clinical presentation of advanced synchronous ACC in our series is in agreement with previous reports and do not suggest bias in enrolment of this retrospective series of patients (4, 6, 10, 16).
Tumor stage, as best defined by ENS@T classification, was confirmed as the keystone of the prognostic stratification of advanced ACC patients. Due to the high number of patients enrolled, we were able to further investigate the prognostic role of the N status together with venous invasion. We identify a deleterious prognostic role of the N1 status in the range of stage IV ACC patient prognosis as previously reported (9, 14) In addition, we confirm the prognostic value of the number of tumor organs including the primary but also the presence of lymph nodes (16 limitation of our study. In addition, it should be kept in mind that the N classification used in our study refers to both imaging and pathological classifications and future refinements are expected. From a therapeutic standpoint, these results may suggest that the surgery of ACC primary tumor including venous invasion is better handled by ACC surgeons than lymph node dissection whose putative role has been only be recently underlined (15, 28) .
In addition to the mENS@T classification, four parameters named GRAF parameters are validated for the first time as additional complementary prognostic parameters in large series of advanced ACC patients after adjustment for tumor burden. GRAF parameters were found to significantly affect the prognosis of each mENSAT stage that should now be reported in all studies that question the role of therapeutic intervention in this rare cancer. To make this new GRAF parameters applicable for physicians in their routine practice but also due to the limited number of patients, we decided to test the prognostic influence of the GRAF parameters within most numerous mENS@T stages namely stage III or IVa . The 5-yr OS prognosis of stage III patients was found to range between 60-70% in <50 yrs-old patients with an incidentally discovered ACC or with R0 status and favourable tumoral grading but dropped to 22% when postoperatively the tumoral grading and R status were both found unfavourable. Within stage IVa patients, the 5-yrs OS prognosis was 15% but was found to range from 0 to 55% in patients with favourable or unfavourable GRAF parameters, suggesting again an overlap between stage III and IVa patients. These results strongly suggest the added value of these GRAF parameters to refine the prognostic stratification of advanced ACC patients and the need for a standardized characterization of each of them. At the end of the day, our results suggest that a 2 month difference in overall survival in phase III trial, as recently reported in the FIRMACT trial, could be easily explained by unbalanced stratification for key prognostic parameters rather than therapeutic intervention. Age was found prognostic in some previous studies dealing with early or all stage ACC patients (4, 17, 23) but not all (16) . It was expressed as a binomial parameter in this study and whether it reflects the host, presence of comorbidities, or is a marker of the tumor biology requires further investigations. The presence of symptoms whatever the subtype, tumor-or hormonerelated, was also found to affect the prognosis with an identical prognostic influence.
Hormonal work-up of ACC patients has been standardized for several years now and most recent series suggest a deleterious prognostic impact of cortisol secretions (17, 19) . Future studies should investigate more precisely how far the magnitude and subtypes of secretions affect the prognosis (17, 19) . In the same line, the general status and presence and type of tumor-related symptoms should now be more precisely defined (4, 6, 10, 16) . The prognostic role of the mitotic index but also of the Ki67 even after adjustment to the stage has been suggested in previous reports (18, 27, 29) . Some authors even proposed proliferative index as a more informative driver of the ACC prognostic classification than TNM stage (18, 27 ).
We do not confirm this hypothesis in advanced ACC patients, especially as a far as a more accurate mENS@T classification is used. For reasons related to the limited number of patients with available Ki67 index, we decided to define the grading as a combination of the medians of the Weiss score and/or Ki67 index. Finally, among the GRAF parameters, grading was found to bring the weakest prognostic information. Whether the weak influence of the grade in our study is explained by a lower prognostic influence of the Weiss score in comparison with Ki67 index as suggested by univariate analysis in our study, methodological issues including absence of standardisation but also lack of pathological data in all patients, or a lower informative value of the primary tumor analysis in advanced ACC, remains to be explored. Standardization of Weiss criteria total score reading and proliferative index analysis in future pathological report is expected to represent a step forward in the evaluation of the prognostic influence of Weiss score and or proliferative index in advanced ACC patients.
Although the authors consider Ki67 as more informative and despite the fact that Ki67 was found significant in a limited subgroup of advanced ACC with Ki67 available at multivariate analysis (data not shown), we suggest to use the combination of these parameters in advanced ACC patients until additional data are provided.
A lower number of studies have focused on the prognostic role of the R status and its role is debated since found prognostic in some studies (4, 9, 30) but not all (16) . Indeed, R status can be considered as a surrogate of the tumor burden but also testifies of the surgeon expertise which objective analysis is difficult. R0 status was found a major prognostic parameter in our study. Interestingly, at univariate analysis, both the R0 status achieved after the resection of the primary but also the primary and metastases was significant, suggesting that the benefit of the R0 status applies not only to the primary but also to the overall tumor mass (data not shown). Obviously clinicians should ensure that life expectancy and hazards of such intervention do not jeopardize the initial medical management.
Strengths of this study include the large number of patients based on national expert
European networks together with prolonged follow-up allowing robust conclusions in this rare cancer. Limitations of this study include its retrospective nature, absence of pathological reports for all patients. Standardization and further validations of the mENS@T-GRAF parameters are however needed within prospective cohort of patients as well as the analysis of the added value of the recently published molecular classification of ACC patients (31) .
Conclusion
To conclude, we validate a new mENSAT classification for advanced ACC and four additional prognostic "GRAF" parameters that include the grading, R status, Age and Functional status. This new mENS@T-GRAF system allows to refine the prognosis of advanced ACC patients and is expected to impact the design of future protocols, the interpretation of retrospective studies and to help in the development of biomarkers. 
